A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review.

Autor: Sharafi F; Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Hasani SA; Cancer Research Center, Department of General Surgery, Shahid Beheshti University of Medical Science, Tehran, Iran., Alesaeidi S; Department of Internal Medicine and Rheumatology, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Kahrizi MS; Alborz University of Medical Sciences, Karaj, Iran., Adili A; Senior Adult Oncology Department, Moffitt Cancer Center, University of South Florida, Tampa, Florida, USA.; Department of Oncology, Tabriz University of Medical Sciences, Tabriz, Iran., Ghoreishizadeh S; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Shomali N; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Tamjidifar R; Department of Medical Biochemistry, Faculty of Medicine, Ege University, Izmir, 35100, Turkey.; Department of Stem Cell, Institute of Health Sciences, Ege University, Izmir, 35100, Turkey., Aslaminabad R; Department of Medical Biochemistry, Faculty of Medicine, Ege University, Izmir, 35100, Turkey., Akbari M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. akbarimo@tbzmed.ac.ir.; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. akbarimo@tbzmed.ac.ir.
Jazyk: angličtina
Zdroj: Cancer cell international [Cancer Cell Int] 2022 Aug 23; Vol. 22 (1), pp. 269. Date of Electronic Publication: 2022 Aug 23.
DOI: 10.1186/s12935-022-02682-z
Abstrakt: A pharmacological class known as immune checkpoint inhibitors (ICIs) has been developed as a potential treatment option for various malignancies, including HCC. In HCC, ICIs have demonstrated clinically significant advantages as monotherapy or combination therapy. ICIs that target programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1), as well as cytotoxic T lymphocyte antigen 4 (CTLA-4), have made significant advances in cancer treatment. In hepatocellular carcinoma (HCC), several ICIs are being tested in clinical trials, and the area is quickly developing. As immunotherapy-related adverse events (irAEs) linked with ICI therapy expands and gain worldwide access, up-to-date management guidelines become crucial to the safety profile of ICIs. This review aims to describe the evidence for ICIs in treating HCC, emphasizing the use of combination ICIs.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje